0 464

Cited 115 times in

Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Curative Resection With Tumor-Specific Mesorectal Excision for Fixed Locally Advanced Rectal Cancer: Impact of Postirradiated Pathologic Downstaging on Local Recurrence and Survival

DC FieldValueLanguage
dc.contributor.author김남규-
dc.contributor.author김호근-
dc.contributor.author노재경-
dc.contributor.author백승혁-
dc.contributor.author성진실-
dc.contributor.author손승국-
dc.contributor.author이강영-
dc.contributor.author조장환-
dc.date.accessioned2015-06-10T12:40:44Z-
dc.date.available2015-06-10T12:40:44Z-
dc.date.issued2006-
dc.identifier.issn0003-4932-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/110249-
dc.description.abstractOBJECTIVE: The purpose of this study was to determine the oncologic outcomes and clinical factors affecting survival in patients who underwent neoadjuvant chemoradiotherapy following tumor specific mesorectal excision for locally advanced, fixed rectal cancer. SUMMARY BACKGROUND DATA: Neoadjuvant chemoradiation therapy has resulted in significant tumor downstaging, which enhances curative resection and subsequently improves local disease control for rectal cancer. However, oncologic outcomes, according to clinical factors, have not yet been fully understood in locally advanced and fixed rectal cancer. METHODS: A total of 114 patients who had undergone neoadjuvant chemoradiation for advanced rectal cancer (T3 or T4 and node positive) were investigated retrospectively. Chemotherapy was administered intravenously with 5-FU and leucovorin during weeks 1 and 5 of radiotherapy. The total radiation dose was 5040 cGY in 25 fractions delivered over 5 weeks. Tumor-specific mesorectal excision was done 4 to 6 weeks after the completion of neoadjuvant chemoradiation. Survival and recurrence rates, according to the pathologic stage, were evaluated. Moreover, factors affecting survival were investigated. RESULTS: The 5-year survival rates according to pathologic stage were: 100% in pathologic complete remission (n = 10), 80% in stage I (n = 23), 56.8% in stage II (n = 34), and 42.3% in stage III (n = 47) (P = 0.0000). Local, systemic, and combined recurrence rates were 11.4%, 22.8%, and 3.5%, respectively. Multivariate analysis showed that the pathologic N stage and operation method were the independent factors affecting survival rate. CONCLUSION: Pathologic complete remission showed excellent oncologic outcomes, and the pathologic N stage was the most important factor for oncologic outcomes.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1024~1030-
dc.relation.isPartOfANNALS OF SURGERY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy*-
dc.subject.MESHNeoplasm Recurrence, Local/mortality-
dc.subject.MESHNeoplasm Recurrence, Local/pathology*-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRectal Neoplasms/mortality-
dc.subject.MESHRectal Neoplasms/pathology*-
dc.subject.MESHRectal Neoplasms/therapy*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTreatment Outcome-
dc.titleOncologic Outcomes After Neoadjuvant Chemoradiation Followed by Curative Resection With Tumor-Specific Mesorectal Excision for Fixed Locally Advanced Rectal Cancer: Impact of Postirradiated Pathologic Downstaging on Local Recurrence and Survival-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorNam Kyu Kim-
dc.contributor.googleauthorSeung Hyuk Baik-
dc.contributor.googleauthorJin Sil Seong-
dc.contributor.googleauthorHoguen Kim-
dc.contributor.googleauthorJae Kyung Roh-
dc.contributor.googleauthorKang Young Lee-
dc.contributor.googleauthorSeung Kook Sohn-
dc.contributor.googleauthorChang Hwan Cho-
dc.identifier.doi10.1097/01.sla.0000225360.99257.73-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00353-
dc.contributor.localIdA01183-
dc.contributor.localIdA01290-
dc.contributor.localIdA01827-
dc.contributor.localIdA01956-
dc.contributor.localIdA01978-
dc.contributor.localIdA02640-
dc.contributor.localIdA03894-
dc.relation.journalcodeJ00178-
dc.identifier.eissn1528-1140 (-
dc.identifier.pmid17122629-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000658-200612000-00024&LSLINK=80&D=ovft-
dc.contributor.alternativeNameKim, Nam Kyu-
dc.contributor.alternativeNameKim, Ho Keun-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameBaik, Seung Hyuk-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameSohn, Seung Kook-
dc.contributor.alternativeNameLee, Kang Young-
dc.contributor.alternativeNameCho, Chang Hwan-
dc.contributor.affiliatedAuthorKim, Nam Kyu-
dc.contributor.affiliatedAuthorKim, Ho Keun-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorBaik, Seung Hyuk-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorSohn, Seung Kook-
dc.contributor.affiliatedAuthorLee, Kang Young-
dc.contributor.affiliatedAuthorCho, Chang Hwan-
dc.rights.accessRightsnot free-
dc.citation.volume244-
dc.citation.number6-
dc.citation.startPage1024-
dc.citation.endPage1030-
dc.identifier.bibliographicCitationANNALS OF SURGERY, Vol.244(6) : 1024-1030, 2006-
dc.identifier.rimsid38062-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.